Quantcast

Epizyme EZH2 Inhibitor — EPZ-6438, Tazemetostat


#21

he has not been called to trial yet. The waiting list is long.


#22

A new press release from Epizyme states that they will not pursue investigating Tazemetostat as monotherapy in synovial sarcoma due to disappointing results:
http://amda-1rbic2.client.shareholder.com/releasedetail.cfm?ReleaseID=1001058